Thymosin Alpha-1
Thymosin alpha-1 (Tα1) is a 28-amino-acid, N-terminally acetylated peptide first isolated from thymus tissue extracts in the 1970s. It corresponds to the N-terminal portion of prothymosin α, a 113-residue precursor protein expressed in many cell types. Tα1 is one of the most studied thymic peptides in immunology and is offered here in 5mg and 10mg vials.
Product Specifications
- Product: Thymosin Alpha-1
- Amount: 5mg / 10mg
- Form: Lyophilized powder
- Purity: Third-party tested by an ISO 17025 U.S. laboratory. See the batch Certificate of Analysis (COA) on this page.
- Storage: Keep sealed and refrigerated at 2–8°C (36–46°F), protected from light.
- Ships from: United States, 2-day UPS
Chemical Profile
- Compound class: 28-amino-acid peptide (N-terminally acetylated)
- Sequence: Ac-Ser-Asp-Ala-Ala-Val-Asp-Thr-Ser-Ser-Glu-Ile-Thr-Thr-Lys-Asp-Leu-Lys-Glu-Lys-Lys-Glu-Val-Val-Glu-Glu-Ala-Glu-Asn-OH (28 residues)
- Molecular formula: C129H215N33O55
- Molecular weight: 3108.3 g/mol
- CAS number: 62304-98-7
What researchers study
Tα1 research centers on how the immune system is regulated rather than on any single tissue:
- Innate immune signaling: Tα1 has been described as acting on toll-like receptors, including TLR2 and TLR9, on myeloid and dendritic antigen-presenting cells, linking innate sensing to adaptive responses.
- T-cell biology: T-cell maturation, cytokine profiles and the balance between helper-cell subsets in cell culture and animal models.
- Infection and tumor models: preclinical models of viral infection and cancer immunology, often in combination with other immune-modulating agents.
- Immune aging: thymic involution and age-related changes in immune function, an area reviewed in 2025.
The compound has a long history, from thymus extracts to a fully synthetic peptide, which makes it a common reference point in reviews of thymic hormones.
Regulatory status
Thymosin alpha-1 is not approved by the FDA. A synthetic form (thymalfasin) is approved as a prescription drug in a number of countries outside the United States and has been evaluated in clinical studies. The material sold here is a research reagent, not that drug product, and is not for human use.
Quality & Documentation
Every batch of Thymosin Alpha-1 is made in small runs for Rogue Compounds and tested by an independent U.S. laboratory for identity (mass spectrometry) and purity (HPLC). Each vial is labeled with its batch number and a QR code that opens the testing lab’s own report for that batch. The same batch Certificate of Analysis is posted on this page and in our COA Library, so you can check one against the other.
Research overview
For a longer look at Thymosin Alpha-1, covering where it came from, what cell and animal studies have measured, and what the evidence does not show, read our Thymosin Alpha-1 research overview. It is written as background reading, and every study it cites is linked to PubMed.
Selected literature
- Garaci E. Thymosin alpha1: a historical overview. Ann N Y Acad Sci. 2007;1112:14-20. PMID 17567941
- Goldstein AL, et al. From lab to bedside: emerging clinical applications of thymosin alpha 1. Expert Opin Biol Ther. 2009;9(5):593-608. PMID 19392576
- Dominari A, et al. Thymosin alpha 1: a comprehensive review of the literature. World J Virol. 2020;9(5):67-78. PMID 33362999
- Simonova MA, et al. Aging and thymosin alpha-1. Int J Mol Sci. 2025;26(23):11470. PMID 41373628
Research Use Only
This product is sold strictly as a research chemical for in-vitro laboratory and analytical use by qualified professionals. It is not a drug, dietary supplement, food, or cosmetic, and it is not intended to diagnose, treat, cure, or prevent any disease. Not for human or veterinary use. Rogue Compounds does not provide dosing, preparation, or usage instructions. The literature on this page is listed for scientific background only and does not describe this product or any use of it.
